Herbal Dispatch Announces Record-Breaking Month of $4.1M in Sales for October 2025November 17, 2025 7:00 AM EST | Source: Herbal Dispatch Inc.Vancouver, British Columbia--(Newsfile Corp. - November 17, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is pleased to announce a record-breaking month of sales for October 2025 and an updated forecast for the fourth quarter of 2025, reflecting continued positive momentum.In October 2025, the ...

Industry Overview - The U.S. cannabis industry is experiencing steady growth, with the legal market generating over $34 billion in annual sales and projections estimating it could reach $60 billion by 2030 due to increased state adoption and product demand [1] - Recent federal discussions on banking reform have positively impacted sector sentiment, as lawmakers are revisiting proposals to ease financial restrictions on licensed operators [1] Company Highlights Trulieve Cannabis Corp. (TCNNF) - Trulieve is a leading multi-state operator with over 200 dispensaries nationwide, primarily in Florida, where it has the largest retail presence [3][6] - The company reported quarterly revenue of approximately $288 million with a gross margin near 59 percent, and year-to-date cash flow from operations exceeded $200 million [6] - Trulieve's focus on improving margins and controlling costs has positioned it as a market leader, despite facing challenges such as heavy tax burdens [6] Cresco Labs Inc. (CRLBF) - Cresco operates over 70 Sunnyside dispensaries across key states and has a strong wholesale platform for branded product distribution [7][9] - The company reported quarterly revenue of nearly $165 million, showing steady growth, and has improved adjusted EBITDA margins through tighter cost controls [9] - Despite posting a net loss due to high interest expenses, Cresco's ability to maintain market share during industry consolidation is a significant strength [9] Verano Holdings Corp. (VRNOF) - Verano operates more than 150 dispensaries, with a strong presence in Florida and other high-value states like New Jersey and Illinois [10][12] - The company achieved quarterly revenue of roughly $203 million, maintaining year-over-year stability, although it faced net losses due to impairment charges [12] - Verano's adjusted EBITDA exceeded $50 million, indicating strong internal financial discipline and a focus on efficiency [12]

Core Insights - The article discusses the launch and evolution of the 420 Investor service, which focuses on cannabis stocks, and its recent move to Seeking Alpha [1] - The analyst expresses a cautious stance on cannabis stocks but highlights Green Thumb Industries (OTCQX:GTBIF) as a favorable investment opportunity [1] Group 1: Company Overview - 420 Investor was established in 2013, coinciding with Colorado's legalization of cannabis for adult use [1] - The service has transitioned to Seeking Alpha, continuing to provide extensive coverage of the cannabis sector [1] - Alan Brochstein, a prominent figure in cannabis investment, has been managing the 420 Investor group and closely monitors 20 cannabis stocks [1] Group 2: Investment Analysis - The analyst downgraded Green Thumb Industries from Hold to Sell when its price was $5.60 in April [1] - The investment group offers various resources, including model portfolios, weekly videos, earnings report previews, and a monthly newsletter [1]

Core Insights - The article discusses the launch of 420 Investor in 2013, coinciding with Colorado's legalization of cannabis for adult use, and its subsequent move to Seeking Alpha in 2023 [1] - The author expresses a cautious stance on cannabis stocks but highlights Green Thumb Industries (OTCQX:GTBIF) as a favorable investment opportunity [1] - The article outlines the services provided by 420 Investor, including model portfolios, videos, and written materials aimed at educating investors about cannabis stocks [1] Company Overview - Green Thumb Industries was previously rated as a "Sell" when its stock price was $5.60 in April, indicating a shift in investment sentiment [1] - The author, Alan Brochstein, has extensive experience in the financial sector, having started in 1986 and focusing on the cannabis industry since 2013 [1] - 420 Investor covers 20 cannabis stocks, providing timely investment news, earnings report previews, and post-report analyses [1] Services Offered - The investing group offers a model portfolio, 10 weekly videos with chart analysis, three summary pieces each week, a monthly newsletter, and a chat feature for investor inquiries [1]

Core Insights - High Tide Inc. is a leading cannabis enterprise focused on retail and community growth, operating the second-largest cannabis retail brand globally and supplying medical cannabis in Germany [3][4] - The company has been recognized for its growth, being named one of Canada's Top Growing Companies for five consecutive years and ranked as a top 50 company by the TSX Venture Exchange in 2022, 2024, and 2025 [4] Company Overview - High Tide operates through its subsidiary Canna Cabana and has multiple global e-commerce platforms for accessories and hemp-derived CBD products [3] - The company has achieved significant recognition, including being ranked number one in the retail category on the Financial Times list of America's Fastest Growing Companies for 2023 [4]

Core Points - MediPharm Labs Corp. has successfully dismissed a $50 million defamation claim against its CEO and Chairman by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][2][3] - The Ontario Superior Court found that the claims were baseless and that the plaintiffs failed to provide evidence of harm caused by the statements made in a letter related to a proxy contest [3] - The company has also reported unauthorized press releases related to Apollo that were disseminated without its consent [4] Company Overview - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [7]

Core Insights - Akanda Corp is researching security requirements for a full cultivation license through its cannabis operating subsidiary, aiming to transition from a hemp cultivation license to a full cultivation license for THC products [1][2] - The company has extended its option on its British Columbia asset for an additional two years, focusing on developing THC and CBD assets while implementing Health Canada-compliant security measures [1][2] - Analysts project that Canada's legal cannabis market will grow from approximately USD $3.25–$3.61 billion in 2024 to about USD $5.8–$7.2 billion by 2030, indicating a compound annual growth rate (CAGR) of 10–12% [3] Company Developments - Akanda plans to design and build security measures that include enhanced perimeter controls, access management, continuous surveillance, and secure storage to support future licensing inspections [1][2] - The company aims to achieve specific milestones related to THC cultivation, product sales, and CBD cultivation, with the completion of security infrastructure being a key enabler for these milestones [2] Market Outlook - The anticipated growth in the Canadian cannabis market presents a significant opportunity for Akanda to leverage its planned security and operational readiness to capture market share [3]

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a moderate growth ranking despite weaker trends across all timeframes, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which viewed the hemp-derived product segment as a key entry point into the U.S. market [8].

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a weaker price trend across all timeframes but a moderate growth ranking, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which had aimed to enter the U.S. market through hemp-derived products [8].

Core Insights - Canopy Growth Corporation reported a narrower-than-expected loss of 1 cent for Q2 fiscal 2026, significantly better than the 95-cent loss from the previous year, although sales fell short of estimates with a 6% year-over-year increase to over $48 million (~C$67 million) [1][10] Group 1: Financial Performance - Cannabis revenues increased by 12% year over year, driven by a 30% rise in adult-use and a 17% increase in medical cannabis sales in Canada [3][4][10] - The overall gross margins for Q2 decreased by 200 basis points to 33%, attributed to lower sales of higher-margin cannabis in international markets and increased inventory provisions [8] - Adjusted EBITDA improved by 45% year over year, aided by lower selling, general and administrative (SG&A) expenses [8][10] Group 2: Market Dynamics - Canopy's cannabis business is expanding in both recreational and medical markets, with strong growth in adult-use and medical cannabis segments across Canada [3] - The international cannabis division faced challenges due to supply-chain issues in Europe, while Storz & Bickel struggled against last year's elevated sales levels [5][6] Group 3: Strategic Initiatives - The company is focusing on streamlining operations by exiting lower-margin businesses and selling non-core assets to enhance liquidity and reduce operating expenses [7] - Canopy aims to achieve sustained profitability through operational efficiencies, improved cultivation yields, and tighter supplier management [9] Group 4: Future Outlook - Canopy anticipates growth acceleration in the second half of fiscal 2026, supported by new product launches and efforts to stabilize its European supply chain [6] - The company expects a rebound in Storz & Bickel revenues in Q3, driven by new product uptake and seasonal demand [6] Group 5: Competitive Landscape - Canopy faces intense competition from other cannabis operators like Aurora Cannabis, Curaleaf Holdings, and Tilray Brands, all pursuing aggressive international expansion and cost-optimization strategies [11] Group 6: Stock Performance and Analyst Sentiment - Canopy Growth's shares have declined by 57% year to date, contrasting with a 3% growth in the industry [12] - Recent upward revisions in bottom-line estimates indicate growing analyst optimism regarding Canopy's operational progress [14][16]